A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group stu... von Schilder, R.J, Sill, M.W, Lankes, H.A, Gold, M.A, Mannel, R.S, Modesitt, S.C, Hanjani, P, Bonebrake, A.J, Sood, A.K, Godwin, A.K, Hu, W, Alpaugh, R.K

Volltext

Associations Between Depressive Symptoms and Sexual Risk Behavior in a Diverse Sample of Female Adolescents von Rubin, A.G., BA, Gold, M.A., DO, Primack, B.A., MD, EdM, MS

Volltext

Does Increased Cost Translate to Increased Efficiency? A Comparison of RUMI I Versus RUMI II von Thomassee, M, Curlin, H, Jones, H.H, Anderson, T.L, Scheib, S.A, Gold, M.A

Volltext

Cervical cancer outcomes in true cut through simple hysterectomy compared to appropriately managed controls von Castellano, T., Driskill, L., Rodriguez, A., Gold, M.A., Landrum, L.M.

Volltext

Neoadjuvant chemotherapy: Patterns of utilization and predictors of surgical resectability von Tuller, E.R, Tillmanns, T.D, Estepp, R.E, Walker, J.L, Gold, M.A, McMeekin, D.S, Moore, K.N

Volltext

Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected? von Elfrink, S.H, Myers, T.K.N, Gold, M.A, Walker, J.L, McMeekin, D.S, Moore, K.N

Volltext

Catheter-Related Complications of Intraperitoneal Chemotherapy as First-Line Treatment for Advanced Epithelial Ovarian Carcinoma von Landrum, L.M, Gold, M.A, Mcmeekin, D.S, Walker, J.L

Volltext

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial von Powell, M.A., Bjørge, L., Willmott, L., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L.M., Gropp-Meier, M., Stuckey, A., Boere, I., Gold, M.A., Segev, Y., Gill, S.E., Gennigens, C., Sebastianelli, A., Shahin, M.S., Pothuri, B., Monk, B.J., Buscema, J., Coleman, R.L., Slomovitz, B.M., Ring, K.L., Herzog, T.J., Balas, M.M., Grimshaw, M., Stevens, S., Lai, D.W., McCourt, C., Mirza, M.R.

Volltext

Primary care provider's perspectives on the challenges of contraceptive counseling von Akers, A.A, Santucci, A, Nikolajski, C.E, Gold, M.A, Schwarz, B

Volltext

Stage IVb Endometrial Cancer: Does Applying an Ovarian Cancer Treatment Paradigm Result in Similar Outcomes? von Landrum, L.M, Moore, K.N, Myers, T.K.N, Lanneau, G.S, Walker, J.L, Gold, M.A

Volltext

Advanced Ovarian Cancer: Is Cure a Reasonable Expectation? von Myers, T.K.N, Moore, K.N, Cofer, A, Landrum, L.M, Gold, M.A, Walker, J.L, McMeekin, D.S

Volltext

Markets and marketing strategies for agroforestry specialty products in North America von Gold, M.A, Godsey, L.D, Josiah, S.J

Volltext

Skirting the issue: communication about contraception and abortion in African-American families von Akers, A.A, Gold, M.A, Corbie-Smith, G, Switzer, G.E, Doswell, W, George, A.E

Volltext

Effect of a brief educational intervention on the attitudes of young women toward the intrauterine device von Whitaker, A.K, Terplan, M, Gold, M.A, Johnson, L.M, Creinin, M.D, Harwood, B

Volltext

Inadequate Vitamin D Status in Adolescents with Substantial Bone Mineral Density Loss During the Use of Depot Medroxyprogesterone Acetate Injectable Contraceptive: A Pilot Study von Harel, Z., MD, Wolter, K., MD, PhD, Gold, M.A., DO, Cromer, B., MD, Bruner, A., MD, Stager, M., MD, Bachrach, L., MD, Hertweck, P., MD, Nelson, A., MD, Nelson, D., MD, Coupey, S., MD, Johnson, C.C., PhD, MPH, Burkman, R., MD, Bone, H., MD

Volltext

AGRICULTURE SCENARIO AND STRATEGIES FOR BIHARS DEVELOPMENT von Ranjan, Priya

Volltext

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizuma... von Moore, K.N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Maenpaa, J., Willmott, L.J., Colombo, N., Thomes-Pepin, J., Gold, M.A., Aghajanian, C., Wu, F., Molinero, L., Khor, V., Lin, Y.G., Pignata, S.

Volltext

Uterine Serous Cancer: Is the GOG 10% Designation Clinically Relevant? von Henretta, M, O'Toole, R, Gold, M.A, Zhang, R.R, Huh, W.K, Conner, M.G, Chen, L, Phillips, G, Cohn, D.E

Volltext

Stage IIIC Endometrial Cancer Should be Further Stratified von Lanneau, G.S, Moore, K.N, Lanneau, M.S, Landrum, L.M, Smith, C, Hagan, C, Gold, M.A, McMeekin, D.S

Volltext

Multiple Factor IIIA Endometrial Cancer is a Marker of Poor Prognosis von Lanneau, G.S, Landrum, L.M, Moore, K.N, Smith, C, Lanneau, M.S, Frank, S, Gold, M.A, McMeekin, D.S

Volltext